Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume
Rockall, Andrea G
Mozley, P David
McNeish, Iain A
Clinical Cancer Research
American Association for Cancer Research.
MetadataShow full item record
Rockall, A. G., Avril, N., Lam, R., Iannone, R., Mozley, P. D., Parkinson, C., Bergstrom, D., et al. (2014). Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Clinical Cancer Research, (2014-02-26)https://doi.org/10.1158/1078-0432.CCR-13-2634
Purpose - Repeatability of baseline FDG-PET/CT measurements has not been tested in ovarian cancer. This dual-center, prospective study assessed variation in tumor FDG uptake, tumor diameter (TD) and tumor volume (TV) from sequential FDG-PET/CT and contrast-enhanced CT (CECT) in patients with recurrent platinum-sensitive ovarian cancer. Methods - Patients underwent two pre-treatment baseline FDG-PET/CT (n=21) and CECT (n=20) at 2 clinical sites with different PET/CT instruments. Patients were included if they had at least one target lesion (TL) in the abdomen with an SUV maximum (SUVmax) of ≥2.5 and a long axis diameter of ≥15mm. Two independent reading methods were used to evaluate repeatability of TD and SUV uptake: on site and at an imaging clinical research organization (CRO). TV reads were only performed by CRO. In each reading set, TLs were independently measured on sequential imaging. Results - Median time between FDG-PET/CT was 2 days (range 1-7). For site reads, concordance correlation coefficient (CCC) for SUVmean, SUVmax and TD were 0.95, 0.94 and 0.99 respectively. Repeatability coefficients were 16.3%, 17.3% and 8.8% for SUVmean, SUVmax and TD respectively. Similar results were observed for CRO reads. TV CCC was 0.99 with a repeatability coefficient of 28.1%. Conclusions - There was excellent test/retest repeatability for FDG-PET/CT quantitative measurements across two sites and two independent reading methods. Cut-off values for determining change in SUVmean, SUVmax and TV establish limits to determine metabolic and/or volumetric response to treatment in platinum-sensitive relapsed ovarian cancer.
Test-retest, FDG-PET/CT, tumor volume, recurrent ovarian cancer
This study was funded by Merck and Co.
Cancer Research UK (CRUK-A10139)
Cancer Research UK (CRUK-A15601)
Cancer Research UK (C14303/A17197)
External DOI: https://doi.org/10.1158/1078-0432.CCR-13-2634
This record's URL: https://www.repository.cam.ac.uk/handle/1810/245481